文献速递消化系统肿瘤

体质指数对结直肠癌术后长期生存结局影响的系统综述与Meta分析

A systematic review and meta-analysis assessing the impact of body mass index on long-term survival outcomes after surgery for colorectal cancer.
PubMed 文献 · Eur J Cancer · 2022-07-05

该系统综述与Meta分析筛选2588篇文献后纳入56篇、共72582例结直肠癌手术患者,比较不同体质指数(BMI)分组的长期生存。BMI<18.5者总生存、癌特异生存、无病生存及无复发生存均显著差于BMI 18.5-25者;BMI>35者多项生存结局亦显著更差;BMI 25-30仅在结肠癌亚组中总生存和无病生存显著改善。

要点

  • BMI<18.5的结直肠癌手术患者总生存显著差于BMI 18.5-25者(HR 1.91,P<0.0001)。
  • BMI>35者较BMI 18.5-25者总生存显著更差(HR 1.24,P=0.02),癌特异生存亦更差(HR 1.36,P=0.01)。
  • BMI 25-30仅在结肠癌亚组中总生存(HR 0.90,P=0.05)和无病生存(HR 0.90,P=0.04)显著改善。

核心结论

  • 结直肠癌手术时体重过低(BMI<18.5)或II/III级肥胖(BMI>35)可能导致长期生存结局更差,而超重(BMI 25-30)可能在结肠癌患者亚组中改善生存。
  • 作者认为优化BMI可能术前改善结直肠癌术后长期生存。

研究设计与样本

  • 系统文献综述与Meta分析,共筛选2588篇文献,纳入56篇,报告72582例参与者。

主要发现

  • BMI<18.5者较BMI 18.5-25者总生存显著更差(HR 1.91,P<0.0001),癌特异生存(HR 1.91,P<0.0001)、无病生存(HR 1.50,P<0.0001)及无复发生存(HR 1.13,P=0.007)亦显著更差。
  • BMI 25-30者与BMI 18.5-25者在总生存、癌特异生存、无病生存及无复发生存上无显著差异,但结肠癌亚组中BMI 25-30者总生存显著改善(HR 0.90,P=0.05)、无病生存显著改善(HR 0.90,P=0.04)。
  • BMI>30者较BMI 18.5-25者无病生存显著更差(HR 1.05,P=0.03),总生存、癌特异生存及无复发生存无显著差异。
  • BMI>35者较BMI 18.5-25者总生存显著更差(HR 1.24,P=0.02)、癌特异生存显著更差(HR 1.36,P=0.01)、无病生存显著更差(HR 1.15,P=0.03),结肠癌无复发生存显著更差(HR 1.11,P=0.04),直肠癌无复发生存显著更差(HR 4.10,P=0.04)。

临床怎么用

  • 作者认为优化BMI可能术前改善结直肠癌术后长期生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of body mass index (BMI) on long-term survival outcomes after colorectal cancer surgery is debated. DESIGN: A systematic literature review and meta-analysis was performed to compare long-term survival outcomes of patients of different BMI categories after colorectal cancer surgery. RESULTS: Of the 2588 articles screened, 56 articles met the inclusion criteria, reporting on 72,582 participants. Patients with BMI <18.5 had significantly worse overall survival [hazard ratio (HR) 1.91; P < 0.0001], cancer-specific survival (HR = 1.91; P < 0.0001), disease-free survival (HR = 1.50; P < 0.0001) and recurrence-free survival (HR = 1.13; P = 0.007) compared to patients with a BMI of 18.5-25. There was no significant difference between those with BMI 25-30 and 18.5-25 in overall survival, cancer-specific survival, disease-free survival and recurrence-free survival, except for the subgroup of patients with colon cancer where patients with BMI 25-30 had significantly improved overall survival (HR = 0.90; P = 0.05) and disease-free survival (HR = 0.90; P = 0.04). Patients with BMI >30 had significantly worse disease-free survival (HR = 1.05; P = 0.03) compared to patients with a BMI of 18.5-25, but no significant difference in overall survival, cancer-specific survival and recurrence-free survival. Patients with BMI >35 compared to 18.5-25 had significantly worse overall survival (HR = 1.24; P = 0.02), cancer-specific survival (HR = 1.36; P = 0.01), disease-free survival (HR = 1.15; P = 0.03) and recurrence-free survival for colon (HR = 1.11; P = 0.04) and rectal (HR = 4.10; P = 0.04) cancer. CONCLUSIONS: Being underweight (BMI < 18.5) or class II/III obese (BMI > 35) at the time of colorectal cancer surgery may result in worse long-term survival outcomes, whereas being overweight (BMI 25-30) may improve survival in a subgroup of patients with colon cancer. Optimising BMI may preoperatively improve long-term survival after surgery for colorectal cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Simillis C, Taylor B, Ahmad A, et al. A systematic review and meta-analysis assessing the impact of body mass index on long-term survival outcomes after surgery for colorectal cancer. Eur J Cancer. 2022. PMID: 35797761. doi:10.1016/j.ejca.2022.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。